日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.

树突状细胞/骨髓瘤融合疫苗联合来那度胺维持治疗多发性骨髓瘤一线自体造血细胞移植的随机 II 期试验:BMT CTN 1401

Chung David J, Shah Nina, Wu Juan, Logan Brent, Bisharat Lina, Callander Natalie, Cheloni Giulia, Anderson Kenneth, Chodon Thinle, Dhakal Binod, Devine Steve, Somaiya Dutt Poorvi, Efebera Yvonne, Geller Nancy, Ghiasuddin Haider, Hematti Peiman, Holmberg Leona, Howard Alan, Johnson Bryon, Karagkouni Dimitra, Lazarus Hillard M, Malek Ehsan, McCarthy Philip, McKenna David, Mendizabal Adam, Nooka Ajay, Munshi Nikhil, O'Donnell Lynn, Rapoport Aaron P, Reese Jane, Rosenblatt Jacalyn, Soiffer Robert, Stroopinsky Dina, Uhl Lynne, Vlachos Ioannis S, Waller Edmund K, Young James W, Pasquini Marcelo C, Avigan David